The vaccine has been licensed in more than 50 countries/regions around the world and has not yet been approved in the United States
London- According to data from an advanced trial of 30,000 volunteers conducted in the United States, the AstraZeneca and Oxford vaccines are 79% effective against symptomatic Covid-19 and 100% effective against severe cases.
The drugmaker said on Monday that data from the advanced AstraZeneca Covid-19 vaccine trial in the United States showed an effective rate of 79%.
Although the AstraZeneca vaccine has been licensed in more than 50 countries/regions around the world, it has not yet been approved in the United States.
In this study, out of 30,000 volunteers, 20,000 received the vaccine and the rest were placebos.
The researchers pointed out that the vaccine is effective in all age groups, including the elderly, which has not been determined in previous studies in other countries.
The first data from the study is part of the information that AstraZeneca must send to the U.S. Food and Drug Administration (FDA).
The FDA advisory committee will openly debate the drug’s evidence before deciding whether to allow emergency use of the vaccine.
Scientists are waiting for the results of the American study, hoping that it can eliminate people’s confusion about the actual effect of this vaccine.
The United Kingdom reported the license for the vaccine based on the results of some trials conducted in the United Kingdom, Brazil and South Africa, and the trial is reported to be 70% effective.
However, these results were affected by manufacturing defects, which caused some participants to receive only half the dose at the first injection, a mistake that the researchers did not realize at first.
Later, there were more questions about providing protection to the elderly and how long to wait between medications.
Some European countries, such as Germany, France and Belgium, initially avoided giving it to the elderly and only changed their policies when new data showed that it could also protect the elderly.
Last week, more than a dozen countries (mainly in Europe) temporarily stopped using the AstraZeneca vaccine. Previously, there were reports that the vaccine was related to blood clots.
On Thursday, the European Medicines Agency concluded after an investigation that the vaccine generally does not increase the risk of blood clots, although it cannot be ruled out that it is related to two very rare clots.
France, Germany, Italy and other countries resumed use of the vaccine on Friday, and several senior politicians welcomed it and reiterated that it is safe.